BMS-708163 - CAS 1146699-66-2
Catalog number: 1146699-66-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
BMS-708163, also called Avagacestat, is a potent, orally bioavailable inhibitor of γ-secretase that more potently inhibits the cleavage of APP (IC50s = 0.30 nM) to Aβ40 than signaling through Notch (IC50s = 58 nM).
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
A potent, orally bioavailable inhibitor of γ-secretase
Solid powder
(2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide; Avagacestat; BMS-708163; 1146699-66-2; BMS 708163; UNII-TQ44WWY45Q; BMS-708163-01; Avagacestat (USAN); Avagacestat [USAN]; (2R)-2-[N-[(4-CHLOROPHENYL)SULFONYL]-N-[2-FLUORO-4-(1,2,4-OXADIAZOL-3-YL)BENZYL]AMINO]-5,5,5-TRIFLUOROPENTANAMIDE; (R)-2-(4-chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide; BMS708163, 1146699-66-2; (2R)-5,5,5-trifluoro-2-(N-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}4-chlorobenzenesulfonamido)pentanamide; 123886-EP2295417A1; (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide; (2R)-2-[[(4-chlorophenyl)-sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide; (2R)-2-[[(4-Chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide; (2R)-2-[[(4-Chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
Soluble to 100 mg/mL in DMSO and 7.5 mg/mL in Ethanol
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -34℃ for long term (months to years).
Boiling Point:
652.258℃ at 760 mmHg
1.488 g/cm3
Canonical SMILES:
1.Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G1, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright C, Dockens RC. Clin Drug Investig. 2012 Nov;32(11):761-9. doi: 10.1007/s40261-012-0006-4.
BACKGROUND: The concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer's disease (AD) pathology, and has been used to evaluate the effectiveness of γ-secretase inhibition. Avagacestat is a selective γ-secretase inhibitor in development for the treatment of AD. The primary objective of this study was to assess the effects of single oral doses of avagacestat on the CSF Aβ concentrations in healthy male subjects. Secondary objectives included single-dose pharmacokinetics in CSF and plasma, safety and tolerability.
2.A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R1, Wang JS, Castaneda L, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Tong G. Clin Pharmacokinet. 2012 Oct 1;51(10):681-93.
BACKGROUND AND OBJECTIVES: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women in a placebo-controlled, sequential-panel, ascending multiple-dose study.
3.Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V1, Salloway S2, van Dyck CH3, Dubois B4, Andreasen N5, Brody M6, Curtis C7, Soininen H8, Thein S9, Shiovitz T10, Pilcher G1, Ferris S11, Colby S1, Kerselaers W1, Dockens R1, Soares H1, Kaplita S1, Luo F1, Pachai C12, Bracoud L12, Mintun M13, Grill JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.
IMPORTANCE: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild cognitive impairment (MCI) symptoms.
4.γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Xie M1, He J, He C, Wei S. J Cell Biochem. 2015 Jun;116(6):1019-27. doi: 10.1002/jcb.25056.
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitor (TKI). Acquired resistance to EGFR TKI develops after prolonged treatment. The aim of this study was to investigate the effect of the novel γ secretase inhibitor BMS-708163 on acquired resistance to the EGFR TKI gefitinib. We did not observe known mechanisms of acquired resistance to EGFR TKI, including the EGFR T790M mutation and MET gene amplification in the gefitinib-resistant PC9/AB2 cells. BMS-708163 inhibited PI3K/Akt expression and sensitized PC9/AB2 cells to gefitinib-induced cytotoxicity. In contrast, BMS-708163 had no significant effect on gefitinib sensitivity in PC9 parental cells. Combined treatment with BMS-708163 and gefitinib induced high levels of apoptosis. Our in vivo studies showed that combined treatment of gefitinib and BMS-708163 inhibited the growth of PC9/AB2 xenografts. In conclusion, our data show that combined treatment of gefitinib and γ secretase inhibitors may be useful for treating lung adenocarcinomas harboring EGFR mutations with acquired gefitinib resistance.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related γ-secretase Products

CAS 677746-25-7 K 01-162

K 01-162
(CAS: 677746-25-7)

K 01-162 binds and destabilizes AβO (β-amyloid( EC50= 0.080 mM; IC50= 80 nM), can reduce the brain amyloid burden that exists in both fibrillar and RIPA-soluble...

CAS 935525-13-6 BMS-433796

(CAS: 935525-13-6)

BMS-433796 is a γ-secretase inhibitor. Chronic dosing of BMS-433796 in Tg2576 mice suggested a narrow therapeutic window and Notch-mediated toxicity at higher d...

CAS 292632-98-5 L-685,458

(CAS: 292632-98-5)

L-685,458, a transition state analogue inhibitor, as a selective and potent inhibitor of γ-secretase (IC50 = 17 nM) it shows > 50-fold selectivity over a variet...

CAS 749269-83-8 CHF 5074

CHF 5074
(CAS: 749269-83-8)

CHF5074, also known as CSP-1103, is a novel γ-secretase modulator. It could reduce Aβ42 and Aβ40 secretion, which IC50 value is 3.6 and 18.4 μM respectively. It...

CAS 161710-10-7 Z-Ile-Leu-aldehyde

(CAS: 161710-10-7)

Z-Ile-Leu-aldehyde, also known as Z-IL-CHO or GSI-XII, inhibits γ-secretase and Notch signaling. In vitro: induces apoptosis of murine MOPC315.BM myeloma cells ...

CAS 471905-41-6 MK-0752

(CAS: 471905-41-6)

MK 0752, a potent, reversible inhibitor of γ-secretase (IC50 ~50 nM), reduces the cleavage of APP to Aβ40 in human neuroblastoma SH-SY5Y cells (IC50= 5 nM).

CAS 1431697-84-5 gamma-secretase modulator 3

gamma-secretase modulator 3
(CAS: 1431697-84-5)

gamma-secretase modulator 3 is a γ-secretase inhibitor.

CAS 209984-58-7 LY-411575 isomer 1

LY-411575 isomer 1
(CAS: 209984-58-7)

LY-411575 isomer 1, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...

CAS 1333990-84-3 ELND006

(CAS: 1333990-84-3)

ELND006 is one of the newest molecules to be reported on regarding the testing of the β-amyloid hypothesis. At the 2010 Alzheimer’s Association International Co...

CAS 1172637-87-4 gamma-secretase modulator 1

gamma-secretase modulator 1
(CAS: 1172637-87-4)

gamma-secretase modulator 1 is a gamma-secretase modulator, useful for Alzheimer's disease.

(CAS: 1402002-76-9)

PF-06442609 is a potent, metabolic stable γ-secretase modulators. It displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain Aβ42 a...

CAS 847925-91-1 RO4929097

(CAS: 847925-91-1)

RO4929097, a small-molecule inhibitor of γ secretase (IC50= 4 nM, EC50= 5 nM), inhibits cellular processing of Aβ40 (EC50= 14 nM) and Notch(EC50= 5 nM). In vitr...

CAS 1146699-66-2 BMS-708163

(CAS: 1146699-66-2)

BMS-708163, also called Avagacestat, is a potent, orally bioavailable inhibitor of γ-secretase that more potently inhibits the cleavage of APP (IC50s = 0.30 nM)...

CAS 937812-80-1 gamma-Secretase modulators

gamma-Secretase modulators
(CAS: 937812-80-1)

gamma-Secretase Modulators, as a potent modulator of γ-secretase, it is derived from oxadiazine. IC50: Aβ42=11 nM, Aβtotal/ Aβ42=1170.

CAS 870843-42-8 E 2012

E 2012
(CAS: 870843-42-8)

E 2012, is a potent selective, orally bioavailable γ-secretase modulator without affecting Notch processing that can used to treat Alzheimer's Disease.

TC-E 5006
(CAS: 1257395-14-4)

TC-E 5006, also called BIIB042, a potent γ-secretase modulator, which lowered Aβ42, increased Aβ38, but had little to no effect on Aβ40 levels both in vitro and...

LY 450139
(CAS: 866488-53-1)

Semagacestat is a gamma-secretase inhibitor originally developed by Eli Lilly. In Aug 2010, Phase-III for Alzheimer's disease was discontinued.

CAS 677772-84-8 MRK 560

MRK 560
(CAS: 677772-84-8)

MRK 560, under the IUPAC name N-((1r,4r)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)-1,1,1-trifluoromethanesulfonamide, is a novel orally bio...

CAS 209984-57-6 LY-411575

(CAS: 209984-57-6)

LY-411575, also known as LSN-411575, is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-basedγ-secretase ass...

CAS 1093978-89-2 gamma-secretase modulator 2

gamma-secretase modulator 2
(CAS: 1093978-89-2)

gamma-secretase modulator 2,a triazole derivative, a potent and selective γ-secretase modulator so as to selectively attenuate production of Aβ(1-42) and hence ...

Chemical Structure

CAS 1146699-66-2 BMS-708163

Quick Inquiry

Verification code

Featured Items